NodThera is a clinical-stage biotechnology company developing a new class of potent and selective NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation. Led by an experienced management team, NodThera is leveraging new insights into inflammasome biology and chemistry to build a clinically advanced portfolio of highly differentiated small molecule NLRP3 inflammasome inhibitors.
Learn more at www.nodthera.com or follow us on LinkedIn.